Kallistatin Linked to Muscle Fat and Reduced Exercise Capacity

Researchers have identified a significant link between Kallistatin and myosteatosis, shedding light on why patients with metabolic disorders often face exercise intolerance. While researchers have long observed intramuscular lipid deposition in diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD), the precise triggers remained unclear. Recent evidence now suggests that Kallistatin, a protein significantly elevated in these conditions, directly impairs muscle function.

Kallistatin serves as a causative factor in hepatic steatosis, but its effects on skeletal muscle are equally profound. High serum levels of this protein correlate with increased muscle triglycerides and a marked decline in physical performance. Specifically, this elevation creates a barrier to efficient energy use within muscle tissues.

Exploring Kallistatin and Myosteatosis Mechanisms

The study indicates that high levels of Kallistatin antagonize the AdipoR1 receptor in skeletal muscle. This antagonism effectively blocks the AdipoR1-mediated AMPK signalling pathway. Because AMPK is a central regulator of lipid oxidation and energy production, its inhibition leads to severe lipid accumulation within muscle fibers. Consequently, muscle tissues experience mitochondrial dysfunction, reduced mitochondrial DNA copy numbers, and lower ATP production.

Furthermore, longitudinal analyses using transgenic mouse models confirmed these findings. These mice developed clear signs of myosteatosis and exhibited significantly lower exercise endurance compared to wild-type controls. Conversely, when researchers utilized genetic ablation to remove Kallistatin, diet-induced muscle lipid deposition improved. This confirms that Kallistatin is not just a marker but a driver of muscle fat accumulation.

Therapeutic Opportunities

Interestingly, the research team explored whether targeting this pathway could reverse the damage. Treatment with AdipoRon, a small-molecule AdipoR1 agonist, successfully mitigated the negative effects of Kallistatin in laboratory myotubes. In addition, using AICAR to activate AMPK also helped bypass the inhibitory effects of the protein. Therefore, restoring AdipoR1-mediated AMPK activity could serve as a viable strategy for managing metabolic-related muscle dysfunction. Target agonists of the Kallistatin-AdipoR1 axis offer a promising therapeutic avenue for patients struggling with the muscular complications of MASLD and diabetes.

Frequently Asked Questions

What is myosteatosis?

Myosteatosis refers to the pathological accumulation of fat within skeletal muscle tissue. This condition is often associated with metabolic disorders and leads to reduced muscle quality and strength.

How does Kallistatin affect exercise capacity?

Elevated Kallistatin blocks the AdipoR1 receptor, which inhibits the AMPK pathway. This inhibition reduces energy production in the mitochondria, leading to muscle fatigue and decreased exercise tolerance.

Can myosteatosis be reversed?

Current research suggests that targeting the Kallistatin-AdipoR1 axis or using AMPK activators like AICAR and AdipoRon may help reduce lipid deposition and improve muscle function.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.

References

Hong F et al. Elevated Kallistatin Induces Myosteatosis and Exercise Intolerance by Antagonizing AdipoR1-Mediated AMPK Signalling. J Cachexia Sarcopenia Muscle. 2026 Apr undefined. doi: 10.1002/jcsm.70261. PMID: 41922933.

Iwabu M et al. Adiponectin and AdipoR1 regulate PGC-1α and mitochondria by Ca2+ and AMPK/SIRT1. Nature. 2010 Mar 31;464(7293):1313-9. doi: 10.1038/nature08979.